Literature DB >> 20733102

Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.

Whady Hueb1, Neuza Lopes, Bernard J Gersh, Paulo R Soares, Expedito E Ribeiro, Alexandre C Pereira, Desiderio Favarato, Antonio Sérgio C Rocha, Alexandre C Hueb, Jose A F Ramires.   

Abstract

BACKGROUND: This study compared the 10-year follow-up of percutaneous coronary intervention (PCI), coronary artery surgery (CABG), and medical treatment (MT) in patients with multivessel coronary artery disease, stable angina, and preserved ventricular function. METHODS AND
RESULTS: The primary end points were overall mortality, Q-wave myocardial infarction, or refractory angina that required revascularization. All data were analyzed according to the intention-to-treat principle. At a single institution, 611 patients were randomly assigned to CABG (n=203), PCI (n=205), or MT (n=203). The 10-year survival rates were 74.9% with CABG, 75.1% with PCI, and 69% with MT (P=0.089). The 10-year rates of myocardial infarction were 10.3% with CABG, 13.3% with PCI, and 20.7% with MT (P<0.010). The 10-year rates of additional revascularizations were 7.4% with CABG, 41.9% with PCI, and 39.4% with MT (P<0.001). Relative to the composite end point, Cox regression analysis showed a higher incidence of primary events in MT than in CABG (hazard ratio 2.35, 95% confidence interval 1.78 to 3.11) and in PCI than in CABG (hazard ratio 1.85, 95% confidence interval 1.39 to 2.47). Furthermore, 10-year rates of freedom from angina were 64% with CABG, 59% with PCI, and 43% with MT (P<0.001).
CONCLUSIONS: Compared with CABG, MT was associated with a significantly higher incidence of subsequent myocardial infarction, a higher rate of additional revascularization, a higher incidence of cardiac death, and consequently a 2.29-fold increased risk of combined events. PCI was associated with an increased need for further revascularization, a higher incidence of myocardial infarction, and a 1.46-fold increased risk of combined events compared with CABG. Additionally, CABG was better than MT at eliminating anginal symptoms. Clinical Trial Registration Information- URL: http://www.controlled-trials.com. REGISTRATION NUMBER: ISRCTN66068876.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733102     DOI: 10.1161/CIRCULATIONAHA.109.911669

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  55 in total

Review 1.  Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials.

Authors:  Samip Vasaiwala; David O Williams
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI.

Authors:  Tassilo Bonzel; Volker Schächinger; Hilmar Dörge
Journal:  Clin Res Cardiol       Date:  2015-10-27       Impact factor: 5.460

Review 3.  Appropriateness of percutaneous coronary intervention: a review.

Authors:  Matthew R Summers; Manesh R Patel
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

4.  Long-term mortality of coronary artery bypass grafting and bare-metal stenting.

Authors:  Chuntao Wu; Songyang Zhao; Andrew S Wechsler; Stephen Lahey; Gary Walford; Alfred T Culliford; Jeffrey P Gold; Craig R Smith; David R Holmes; Spencer B King; Robert S D Higgins; Desmond Jordan; Edward L Hannan
Journal:  Ann Thorac Surg       Date:  2011-10-19       Impact factor: 4.330

5.  Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy.

Authors:  Javaid Iqbal; Patrick W Serruys
Journal:  Ann Transl Med       Date:  2017-03

Review 6.  [National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].

Authors:  K Werdan
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

Review 7.  Conservative strategy for treatment of stable coronary artery disease.

Authors:  Paulo Cury Rezende; Thiago Luis Scudeler; Leandro Menezes Alves da Costa; Whady Hueb
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

8.  Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase.

Authors:  I Marini; R Moschini; A Del Corso; U Mura
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

Review 9.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

Review 10.  Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Authors:  Gregg W Stone; Judith S Hochman; David O Williams; William E Boden; T Bruce Ferguson; Robert A Harrington; David J Maron
Journal:  J Am Coll Cardiol       Date:  2015-11-23       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.